A Phase II HIV Antiviral from France Has Promising Results

13/01/2016 - 3 minutes

Abivax in Paris (France) has released its phase IIa clinical results for an antiviral therapy for patients with HIV infection, which could potentially take a corner in an annual $18Bn market.

abivax_hiv_antiviral_phase_IIHIV and AIDs have a long-standing history (the quick – yet fascinating story of which can be read here), and since 1983 (when the HIV virus was identified to be responsible for this mystery disease) the WHO estimates 25 million to have died from its grasp.

ABX464 is a first-in-class orally available antiviral drug candidate for the treatment of patients with HIV infection. It blocks HIV replication through a unique mechanism of action that leads to the destruction of viral RNA. Abivax’s RNA Splicing platform has been developed in partnership with the French National Centre for Scientific Research (CNRS) in Montpellier, and the Institut Curie in Paris.

Abivax is also the first company to have established “a fruitful collaboration” with the Cuban Centre for Genetic Engineering and Biotechnology (CGIB) in Havana,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member